Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study

Table 1 Demographic data and timing of everolimus switch and creatinine results

Patient ID	Age	Gender	Pre-transplant diabetes	Time from KT to switch (years)	Cr before switch (mg/dL)	Cr 1 month after (mg/dL)
KT-01	59	Male	Yes	2.5	1.13	1.22
KT-02	49	Male	No	2.3	1.30	1.18
KT-03	35	Male	No	2.8	1.27	0.98
KT-04	63	Male	Yes	1.9	0.78	1.21
KT-05	28	Female	No	1.2	1.59	1.17
KT-06	41	Male	No	2.4	1.57	1.76
KT-07	59	Male	Yes	2.5	1.45	1.02
KT-08	39	Male	Yes	2.1	1.34	1.98
KT-09	43	Female	Yes	2.5	0.80	1.07
KT-10	31	Male	Yes	0.8	1.26	1.25
KT-11	31	Female	Yes	2.0	1.29	1.70
KT-12	44	Male	Yes	1.9	1.08	0.90
KT-13	56	Male	No	1.1	1.38	1.47
KT-14	60	Male	Yes	1.2	1.64	1.89
KT-15	44	Female	Yes	1.1	2.32	0.75
KT-16	23	Female	No	2.3	1.53	1.45
KT-17	42	Male	Yes	1.6	1.57	1.48
KT-18	22	Male	No	2.0	1.42	1.68
KT-19	44	Male	Yes	2.8	0.60	0.90
KT-20	64	Male	No	1.5	1.44	0.87
KT-21	50	Male	No	1.8	1.48	1.58
KT-22	58	Female	Yes	2.5	2.58	1.50
KT-23	22	Male	Yes	1.5	1.36	1.48
KT-24	41	Male	No	1.2	1.59	1.52
KT-25	53	Male	No	1.6	1.43	1.11
KT-26	32	Female	No	1.3	0.91	1.47
KT-27	42	Male	No	2.9	1.98	1.49
KT-28	64	Female	Yes	2.6	1.80	1.10
KT-29	45	Female	Yes	0.8	1.81	2.11
KT-30	69	Male	Yes	2.7	1.03	1.56
KT-31	47	Male	No	2.6	2.10	0.92
KT-32	62	Female	No	1.4	0.81	1.64
KT-33	48	Male	Yes	2.8	1.72	1.40
KT-34	36	Male	Yes	2.1	2.46	1.69
KT-35	35	Male	Yes	2.6	0.99	2.03
KT-36	67	Male	Yes	2.8	1.19	1.06

KT: Kidney transplantation; Cr: Creatinine.

Table 2 Serum creatinine levels before and after initiation of everolimus

Serum creatinine (mg/dL)	Mean	SD	P value
Before everolimus	1.44	0.46
After everolimus (post one month)	1.38	0.35	0.475
After everolimus (post one year)	1.41	0.44	0.398

P < 0.05.

Table 3 Quantitative analysis: Proteinuria levels before and after initiation of everolimus

Mean urinary protein (mg/dL)		SD
Before everolimus	87.84	141.60
After everolimus	64.31	117.44

P < 0.05.

Table 4 Qualitative analysis: Proteinuria levels before and after initiation of everolimus, n (%)

Parameters	Number of patients			Total patients	P value
	Before	After
Protein level not found	16 (44.4)		0 (0)	16 (44.40)	0.005a
Protein level not reported	1 (2.7)		1 (2.7)	1 (2.7)
Protein level detected	7 (19.4)		12 (33.3)	19 (52.7)
Total	24 (66.6)		13 (36.1)	36 (100)

^aP < 0.05.

Table 5 Trough levels of everolimus and tacrolimus at different time intervals

Time	Everolimus trough levels, mean value (ng/dL)	P value	Tacrolimus trough levels, mean value (ng/dL)	P value
At week 1	3.86	0.726	4.82	0.399
Post 6 months	3.82	0.078	4.66	0.002a
Post 1 year	3.65	0.071	3.92	0.000a

^aP < 0.05.